PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

Key Points

Overall survival rates increased with consolidation durvalumab in unresectable stage III NSCLC, and no progression was noted post-chemoradiotherapy.
The treatment explored the impact of durvalumab on patients who did not progress after receiving chemoradiotherapy.
Phase III clinical trial analyzed the efficacy of durvalumab as a consolidation therapy for NSCLC.
The findings may highlight the potential for improved patient management in advanced lung cancer cases.

We only have this paper's title and publication details.

Clinical trial shows durvalumab improves outcomes in unresectable NSCLC, indicating benefits after chemoradiotherapy.

Nct03706690.

No takes yet. Share an insight, caveat, or question.

Wu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share